New data reveals the significant potential of artificial intelligence in pharmaceutical safety monitoring. A study in Drug Safety demonstrates that large language models can automatically identify adverse drug events from clinical notes with 88% accuracy in event identification and 95% in initial clinical note processing. This performance substantially outpaces the capacity of traditional manual review systems, which struggle to systematically examine unstructured clinical documentation across large healthcare networks. The technology achieves 82% accuracy in safety signal detection, identifying potentially hazardous drug interactions and adverse outcomes that conventional pharmacovigilance approaches might overlook. By automating what previously required expert human review, these AI systems could dramatically accelerate the detection timeline for emerging safety signals, enabling healthcare regulators and pharmaceutical companies to respond more rapidly to potential risks. Read the full article on GMJ Newsroom.
Was this article helpful?
